twinfilin actin binding protein 1Genealiases: A6 · PTK9
Q-omics provides the consensus-scored TWF1 profile across patient tissues and cancer cell-line models. TWF1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TWF1 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, TWF1 protein abundance shows 23,488 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight LUAD, KIRP, and HNSC as cancer lineages where TWF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TWF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TWF1 survival associations across molecular data types. TWF1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TWF1 RNA expression–survival associations across cancer types. High TWF1 expression shows unfavorable associations in LUAD, MESO, LIHC, CESC, KIRP and PAAD. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for TWF1 RNA expression.
This table summarizes TWF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TWF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TWF1 shows higher tumor expression in KIRP, LIHC, LUAD, HNSC, LUSC and BRCA. The KIRP box plot shows higher TWF1 RNA expression in tumor versus normal tissue (log2 FC = +0.805, t-test p < 0.001).
This table shows molecular features associated with TWF1 in patient tissues and cancer cell lines. In patient samples, TWF1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, TWF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
